Pharma major Pfizer Inc. (PFE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to its supplemental New Drug Application(sNDA)for XALKORI (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.
from RTT - Biotech https://ift.tt/2RPo4H5
via IFTTT
No comments:
Post a Comment